Stryker Co. (NYSE:SYK) Shares Bought by Ironwood Investment Counsel LLC

Ironwood Investment Counsel LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,323 shares of the medical technology company’s stock after purchasing an additional 30 shares during the period. Ironwood Investment Counsel LLC’s holdings in Stryker were worth $1,196,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in SYK. First National Trust Co boosted its stake in shares of Stryker by 4.7% during the 4th quarter. First National Trust Co now owns 18,187 shares of the medical technology company’s stock worth $6,548,000 after acquiring an additional 820 shares in the last quarter. Atala Financial Inc acquired a new position in shares of Stryker in the 4th quarter valued at $53,000. LBP AM SA raised its holdings in Stryker by 2.9% during the 4th quarter. LBP AM SA now owns 205,810 shares of the medical technology company’s stock worth $74,102,000 after buying an additional 5,853 shares during the period. Impact Capital Partners LLC purchased a new stake in Stryker during the fourth quarter valued at about $639,000. Finally, DecisionMap Wealth Management LLC acquired a new position in shares of Stryker in the fourth quarter worth about $280,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Stock Down 0.0 %

SYK opened at $363.79 on Friday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The business has a 50 day moving average of $382.87 and a 200-day moving average of $373.26. The stock has a market capitalization of $138.81 billion, a price-to-earnings ratio of 46.88, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company earned $3.46 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. Citigroup restated a “buy” rating and set a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. Canaccord Genuity Group upped their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.